EUVIMEDEUVIMED entdecken
Open Access

Cardiovascular and Kidney Outcomes following Sodium-Glucose Cotransporter 2 Inhibitor Initiation in CKD

Joakim Österman iD, Ehab Al-Sodany, Peter Hemmingsson iD, Ida Haugen Löfman, Peter Barany iD, Marie Evans iD

Clinical Journal of the American Society of Nephrology · 2026-10 · 21 (10) · 1733-1743

DOI: 10.2215/cjn.0000001160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 06.08.2026. Verfasst von Joakim Österman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Intervention and Technology (CLINTEC), Renal Medicine, Karolinska Institutet, Huddinge, Sweden. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Cardiovascular Diseases. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AstraZeneca Mölndal, Stockholm läns landsting, Stiftelsen Stig och Gunborg Westman, Stiftelsen för njursjuka, AstraZeneca Mölndal, Stockholm läns landsting.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points In nationwide nephrology-referred CKD, sodium-glucose cotransporter 2 inhibitor use was associated with lower cardiovascular event and KRT risk. Associations with cardiovascular events and KRT were consistent in advanced CKD, a group underrepresented in trials. Findings supported the applicability of trial results to a broad nephrology-referred CKD population.

Background

Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) reduce cardiovascular (CV) and kidney events in randomized trials, yet evidence on their effectiveness in routine nephrology practice remains limited. We examined CV and kidney outcomes associated with SGLT2 inhibitor initiation in adults with CKD receiving specialist nephrology care.

Methods

In this nationwide cohort study, we included adults with CKD receiving specialist nephrology care, identified through the Swedish Renal Registry between January 1, 2016, and December 31, 2023. Participants had baseline data on eGFR, urine albumin-to-creatinine ratio, and hemoglobin; those with prior KRT were excluded. Follow-up continued until December 31, 2024. SGLT2 inhibitor use was identified through national pharmacy records and analyzed according to an intention-to-treat approach. Outcomes were major adverse cardiovascular events (MACE), initiation of KRT, all-cause mortality, and a composite of heart failure hospitalization or CV death. Associations were estimated using inverse probability–weighted marginal structural models to address time-dependent confounding.

Results

Among 32,856 participants (median age 73 years [interquartile range, 63–79]; 36% women; mean eGFR 29.3±16.8 ml/min per 1.73 m 2 ), 1493 (4.5%) were prevalent SGLT2 inhibitor users at baseline and 3491 (10.6%) initiated treatment during follow-up (4984 ever-exposed, 15.2%). SGLT2 inhibitor use was associated with a lower risk of MACE (odds ratio 0.80, 95% confidence interval, 0.71 to 0.91) and KRT (0.67, 0.52 to 0.85). No associations were observed for all-cause mortality (0.95, 0.79 to 1.15) or the composite heart failure outcome (0.87, 0.65 to 1.16), although a lower risk was observed in the incident-user analysis (0.61, 0.38 to 0.98). Associations were generally consistent across prespecified subgroups.

Conclusions

In adults with CKD managed in specialist nephrology care, SGLT2 inhibitor use was associated with a lower risk of MACE and KRT, extending randomized trial evidence to a broad, real-world CKD population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicCardiovascular DiseasesHumansSwedenFemaleMaleMiddle AgedAgedRegistriesGlomerular Filtration RateCohort Studies

Stichwörter der Autor:innen

CKDKRTSGLT2 inhibitorsalbuminuriacardiovascular eventscohort studiesepidemiology and outcomesprogression of kidney disease

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Intervention and Technology (CLINTEC), Renal Medicine, Karolinska Institutet, Huddinge, Sweden.
  • Department of Medicine Solna, Unit of Cardiology, Heart and Vascular Theme, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Joakim Österman, Peter Hemmingsson, Peter Barany, Marie Evans

Förderung

  • AstraZeneca Mölndal, Stockholm läns landsting, Stiftelsen Stig och Gunborg Westman, Stiftelsen för njursjuka
  • AstraZeneca Mölndal
  • Stockholm läns landsting
  • Stiftelsen Stig och Gunborg Westman
  • Stiftelsen för njursjuka

Zitieren

APA

Österman, J., Al-Sodany, E., Hemmingsson, P., Löfman, I. H., Barany, P., & Evans, M. (2026). Cardiovascular and Kidney Outcomes following Sodium-Glucose Cotransporter 2 Inhibitor Initiation in CKD. Clinical Journal of the American Society of Nephrology, 21(10), 1733-1743. https://doi.org/10.2215/cjn.0000001160

Vancouver

Österman J, Al-Sodany E, Hemmingsson P, Löfman IH, Barany P, Evans M. Cardiovascular and Kidney Outcomes following Sodium-Glucose Cotransporter 2 Inhibitor Initiation in CKD. Clinical Journal of the American Society of Nephrology. 2026;21(10):1733-1743. doi:10.2215/cjn.0000001160

BibTeX
@article{sterman2026,
  author = {Österman, Joakim and Al-Sodany, Ehab and Hemmingsson, Peter and Löfman, Ida Haugen and Barany, Peter and Evans, Marie},
  title = {Cardiovascular and Kidney Outcomes following Sodium-Glucose Cotransporter 2 Inhibitor Initiation in CKD},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  volume = {21},
  number = {10},
  pages = {1733--1743},
  doi = {10.2215/cjn.0000001160}
}
Kostenlos starten →